Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 193Recurrence 48Neoplasms, Plasma Cell 19Neoplasms 13Immunoglobulin Light-chain Amyloidosis 10Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Myeloproliferative Disorders 4Lymphoma, B-Cell 4Hematologic Diseases 4Amyloidosis 4Waldenstrom Macroglobulinemia 3Sarcoma, Kaposi 3Renal Insufficiency 3Primary Myelofibrosis 3Polycythemia Vera 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Disease Progression 2Chromosome 17 deletion 2Central Nervous System Neoplasms 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 6TH 302 4Radiotherapy 4pimonidazole 3fluoroazomycin arabinoside 3Propofol 3Injections 3Positron Emission Tomography Computed Tomography 2Blood Specimen Collection 2Bacterial Load 2pomalidomide 1pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1fludarabine 1Tirapazamine 1Temozolomide 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Pancreaticoduodenectomy 1Paclitaxel 1Oxygen 1Nitroglycerin 1Nimorazole 1NVP-BKM120 1Metformin 1Magnetic Resonance Spectroscopy 1Ketamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypoxia × pomalidomide × Clear all
NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡